Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Efficacy and Safety Study of GP681 Tablets for Post-exposure Prophylaxis Against Influenza in Adults and Adolescents

NCT06574503 is registered in ClinicalTrials.gov with Jiangxi Qingfeng Pharmaceutical Co. Ltd. as lead sponsor.

NCT NCT06574503
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06574503 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Clinical Efficacy and Safety Study of GP681 Tablets for Post-exposure Prophylaxis Against Influenza in Adults and Adolescents
Lead sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
December 1, 2024
Completion date
December 30, 2027
Enrollment
748 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza